Johnson & Johnson Launches New Pulsed Field Ablation Device in Europe

The VARIPULSE Pro is the latest addition to the company's cardiac ablation portfolio.

Apr. 7, 2026 at 1:43pm

Got story updates? Submit your updates here. ›

An extreme close-up X-ray-style illustration of a human heart with the VARIPULSE Pro device visible as a glowing, ghostly outline, conceptually representing the innovative cardiac ablation technology.The VARIPULSE Pro device from Johnson & Johnson, designed to treat cardiac arrhythmias using pulsed field ablation technology, is revealed in an X-ray-style illustration.Irvine Today

Johnson & Johnson has announced the launch of its new VARIPULSE Pro pulsed field ablation device in Europe. The VARIPULSE Pro is the latest addition to the company's cardiac ablation portfolio, which uses electrical pulses to treat abnormal heart rhythms.

Why it matters

Pulsed field ablation is an emerging technology in the treatment of cardiac arrhythmias, offering potential advantages over traditional radiofrequency ablation. The launch of the VARIPULSE Pro expands Johnson & Johnson's presence in this growing market and provides European physicians with a new tool to treat patients with heart rhythm disorders.

The details

The VARIPULSE Pro device uses pulsed electric fields to selectively target and ablate cardiac tissue, aiming to improve procedural efficiency and safety compared to radiofrequency ablation. The device is designed to provide physicians with greater control and flexibility during cardiac ablation procedures.

  • Johnson & Johnson announced the launch of the VARIPULSE Pro on April 7, 2026.

The players

Johnson & Johnson

A multinational pharmaceutical and medical devices company that develops medical devices, pharmaceutical, and consumer packaged goods.

Got photos? Submit your photos here. ›

What’s next

The VARIPULSE Pro device is currently available for use in Europe, and Johnson & Johnson plans to seek regulatory approval for the device in additional markets in the future.

The takeaway

The launch of the VARIPULSE Pro device represents an important advancement in Johnson & Johnson's cardiac ablation portfolio, providing European physicians with a new tool to treat patients with heart rhythm disorders using pulsed field ablation technology.